Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Isolation of Lipid Droplets from Acute Myeloid Leukemia Cells for Lipidomic Analysis

Ran Zhao, Liang Zhang, Kazuharu Kamachi, Saurabh Kumar Gupta, Hiroki Akiyama, Jalen Nguyen, Michael Andreeff, Jo Ishizawa, Alessia Lodi

Blood (2024) 144 (Supplement 1): 7502.

https://doi.org/10.1182/blood-2024-201676

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Swati Goel, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 999.

https://doi.org/10.1182/blood-2024-211587

Published: 2024

Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2024-200331

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

Liang Zhang, Ran Zhao, Hiroki Akiyama, Jalen Nguyen, Kazuharu Kamachi, Saurabh Kumar Gupta, Valeria Impedovo, G. Lavender Hackman, Michael Andreeff, Alessia Lodi, Jo Ishizawa

Blood (2024) 144 (Supplement 1): 1400.

https://doi.org/10.1182/blood-2024-208616

Published: 2024

Journal Articles

Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia

Kazuharu Kamachi, Hiroki Akiyama, Ran Zhao, Liang Zhang, Saurabh Kumar Gupta, Lauren B. Ostermann, Yuji Otsuki, Osamu Nagano, Hideyuki Saya, Ayumu Taguchi, Michael Andreeff, Jo Ishizawa

Blood (2024) 144 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2024-201661

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Blood (2024) 144 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2024-198928

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Ekatherine Asatiani, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1813.

https://doi.org/10.1182/blood-2023-188051

Published: 2023

Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2023-187795

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Journal Articles

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Matthew Tcheng, Priyanka Sharma, Ran Zhao, Lauren B. Ostermann, Samar Yazdani, Arman Moayed, Zdzislaw Szulc, Natalia Oleinik, Po Yee Mak, Vivian Ruvolo, Bing Z. Carter, Besim Ogretmen, Gautam Borthakur, Aaron D. Schimmer, Michael Andreeff, Jo Ishizawa

Blood (2023) 142 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2023-181410

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Yuki Nishida, Natalia Baran, Ziyi Li, Lauren B Ostermann, Po Yee Mak, Edward Ayoub, Sujan Piya, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Blood (2022) 140 (Supplement 1): 8785–8786.

https://doi.org/10.1182/blood-2022-162354

Published: 2022

Journal Articles

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Hiroki Akiyama, Natalia Baran, Tom Lesluyes, Lauren B Ostermann, Bin Liu, Jo Ishizawa, Joseph D. Khoury, Marina Konopleva, Peter Van Loo, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5876–5878.

https://doi.org/10.1182/blood-2022-167859

Published: 2022

Journal Articles

Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Adam Rahhal, Yuki Nishida, Edward Ayoub, Lauren B Ostermann, Michael Andreeff, Jo Ishizawa

Blood (2021) 138 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2021-148248

Published: 2021

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Rafael Heinz Montoya, BS, Kiyomi Morita, MDPhD, Tomoyuki Tanaka, MDPhD, Feng Wang, PhD, Koichi Takahashi, MD PhD, Jo Ishizawa, MDPhD, Prasanna Kumar, PhD, Parul Patel, PhD, Cedric E. Dos Santos, PhD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142794

Published: 2020

Journal Articles

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Jo Ishizawa, MDPhD, Edward Ayoub, PhD MS, BSc, Rafael Heinz Montoya, BS, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Naval Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140768

Published: 2020

NARROW

Isolation of Lipid Droplets from Acute Myeloid Leukemia Cells for Lipidomic Analysis

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only